Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer

Clinical Cancer Research

Volumn 6, Issue 6, 2000, Pages 2356-2362

  Colomer, Ramon ^a   Montero, Sagrario ^a   Lluch, Ana ^b   Ojeda, Belén ^c   Barnadas, Agustí ^d   Casado, Antonio ^e   Massutí, Bartomeu ^f   Cortés Funes, Hernán ^a   Lloveras, Belén ^g  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b Hospital Clinic   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION FUNCTION; DISEASE ASSOCIATION; DRUG EFFICACY; ENZYME IMMUNOASSAY; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; ONCOGENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CA-15-3 ANTIGEN; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MULTIVARIATE ANALYSIS; PACLITAXEL; PROSPECTIVE STUDIES; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, ERBB-2; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034082031     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Slamon, D. L., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., and McGuire, W. L. Human breast cancer: correlation of relapse and survival with amplification of her-2/neu oncogene. Science (Washington DC), 235: 177-182, 1987.
2. Dougall, W. C., Qian, X., Peterson, N. C., Miller, M. J., Samanta, A., and Greene, M. I. The neu-oncogene: signal transduction pathways, transformation mechanisms and evolving therapies. Oncogene, 9: 2109-2123, 1994.
3. Mielke, S., Meden, H., Raab, T., Wuttke, W., and Kuhn, W. Effects of interfering and influencing factors on the analyses of p105 (c-erbB-2/HER-2) oncoprotein fragment in serum. Anticancer Res., 17: 3125-3227, 1997.
4. Wu, J. T., Zhang, P., Astill, M. E., Lyons, B. W., and Wu, L. H. Identification and characterization of c-erbB-2 proteins in serum, breast tumor tissue, and SK-BR-3 cell line. J. Clin. Lab. Anal., 9: 141-150, 1995.
5. Paik, S., Hazan, R., Fisher, E. R., Sass, R. E., Fisher, B., Redmond, C., Schlessinger, J., Lippman, M. E., and King, C. R. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein expression in primary breast cancer. J. Clin. Oncol., 8: 103-112, 1990.
6. Fehm, T., Maimonis, P., Weitz, S., Teramoto, Y., Katalinic, A., and Jager, W. Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients. Breast Cancer Res. Treat., 43: 87-95, 1997.
7. Ross, J. S., and Fletcher, J. A. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist, 3: 237-252, 1998.
8. Makris, A., Powles, T. J., Dowsett, M., Osborne, C. K., Trott, P. A., Fernando, I. N., Ashley, S. E., Ormedod, M. G., Titley, J. C., Gregory, R. K., and Allred, D. C. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res., 3: 593-600, 1997.
9. Vargas-Roig, L. M., Gago, F. E., Tello, O., Martin de Civetta, M. T., and Ciocca, D. R. c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy. Int. J. Cancer, 84: 129-134, 1999.
10. Wright, C., Cairns, J., Cantwell, B. J., Cattan, A. R., Hall, A. G., Harris, A. L., and Home, C. H. W. Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases. Br. J. Cancer, 65: 271-274, 1992.
11. Fehm, T., Maimonis, P., Katalinic, A., and Jager, W. H. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology, 55; 33-38, 1998.
12. Gusterson, B. A., Gelber, R. D., Goldhirsh, A., Price, K. N., Save-Soderborgh, J., Anbazhagan, R., Styles, J., Rudenstam, C. M., Golouh, R., Reed, R., Martinez-Tello, F., Tiltman, A., Torhorst, J., Grigolato, P., Bettelheim, R., Neville, A. M., Burki, K., Castiglione, M., Collins, J., Lindtner, J., and Senn, H-J. Prognostic importance of c-erbB-2 expression in breast cancer. J. Clin. Oncol., 10: 1049-1056, 1992.
13. Allred, D. C., Clark, G. M., Tandon, A. K., Molina, R., Tormey, D. C., Osborne, C. K., Gilchrist, K. W., Mansour, E. G., Abeloff, M., Eudey, L., and McGuire, W. L. HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma. J. Clin. Oncol., 10: 599-605, 1992.
14. Miles, D. W., Harris W, H., Gilett, C. E., Smith, P., and Barnes, D. Effect of c-erbB2 and estrogen receptor status on survival of women with primary breast cancer treated with adjuvant cyclophosphamide/ methotrexate/fluorouracil. Int. J. Cancer, 84: 354-359, 1999.
15. Stal, O., Sullivan, S., Wingren, S., Skoog, L., Rutqvist, L. E., Carstensen, J. M., and Nordenskjold, B. c-erbB-2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur. J. Cancer, 31A: 2185-2190, 1995.
16. Muss, H. B., Thor, A. D., Berry, D. A., Kute, T., Liu, E. T., Koerner, F., Cirrincione, C. T., Budman, D. R., Wood, W. C., Barcos, M., and Henderson, I. C. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N. Engl. J. Med., 330: 1260-1266, 1994.
17. Paik, S., Bryant, J., Park, C., Fisher, B., Tan-Chiu, E., Hyams, D., Fisher, E. R., Lippman, M. E., Wickerham, D. L., and Wolmark, N. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J. Natl. Cancer Inst., 90: 1361-1370, 1998.
18. Clahsen, P. C., van de Velde, C. J., Duval, C., Pallud, C., Mandard, A. M., Delobelle-Deroide, A., van den Broek, L., Sahmoud, T. M., and van de Vijver, M. J. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J. Clin. Oncol., 16: 470-479, 1998.
19. Colomer, R., Ruibal, A., and Salvador, L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer (Phila.), 64: 1674-1681, 1989.
20. Carney, W. O., Hamer, P. J., Petit, D., Retos, C., Greene, R., Zabrecky, J. R., McKenzie, S., Hayes, D., Kufe, D., DeLellis, R., Naber, S., and Wolfe, H. Detection and quantitation of the human neu oncoprotein. J. Tumor Mark. Oncol., 6: 53-72, 1991.
21. Montero, S., Guzman, C., Vegh, I., Hitt, R., Cortes-Funes, H., and Colomer, R. Circulating Neu oncogene product in metastatic breast cancer. Proc. Annu. Meet. Am. Assoc. Cancer Res., 35: A1338, 1994.
22. Kath, R., Hoffken, K., Otte, C., Metz, K., Scheulen, M. E., Hulskamp, F., and Seeber, S. The neu-oncogene product in serum and tissue of patients with breast carcinoma. Ann. Oncol., 4: 585-590, 1993.
23. Molina, R., Jo, J., Filella, X., Zanon, G., Pahisa, J., Muñoz, M., Farrus, B., Latre, M. L., Escriche, C., Estape, J., and Mallesta, A. M. c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value. Breast Cancer Res. Treat., 51: 109-119, 1998.
24. Yamauchi, H., O'Neill, A., Gelman, R., Carney, W., Tenney, D. Y., Hosch, S., and Hayes, D. F. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J. Clin. Oncol., 15: 2518-2525, 1997.
25. Colomer, R., Llombart, A., Lluch, A., Ojeda, B., Barnadas, A., Carañana, V., Fernández, Y., De Paz, L., Guillem, V., Montero, S., and Alonso, S. Biweekly paclitaxel and gemcitabine in advanced breast cancer: Phase II trial and predictive value of HER2 extracellular domain (ECD). Proc. Am. Soc. Clin. Oncol., 2000.
26. Thor, A. D., Berry, D. A., Budman, D. R., Muss, H. B., Kute, T., Henderson, I. C., Barcos, M., Cirrincione, C., Edgerton, S., Allred, C., Norton, L., and Liu, E. T. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl. Cancer Inst., 90: 1346-1360, 1998.
27. Rozan, S., Vincent-Salomon, A., Zafrani, B., Validire, P., De Cremoux, P., Bernoux, A., Nieruchalski, M., Fourquet, A., Clough, K., Dieras, V., Pouillart, P., and Sastre-Garau, X. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer, 79: 27-33, 1998.
28. Niskanen, E., Blomqvist, C., Franssila, K., Hietanen, P., and Wasenius, V. M. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer. Br. J. Cancer, 76: 917-922, 1997.
29. Press, M. F., Hung, G., Godolphin, W., and Slamon, D. J. Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression. Cancer Res., 54: 2771-2777, 1994.
30. Charpin, C., De Victor, B., Andrac, L., Amabile, J., Bergeret, D., LaVaut, M. N., Allasia, C., and Piana, L. p53 quantitative immunocytochemical analysis in breast carcinomas. Hum. Pathol., 26: 159-166, 1995.
31. Baselga, J., Seidman, A. D., Rosen, P. P., and Norton, L. HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications. Oncology (Huntingt.), 11: 43-48, 1997.
32. Yu, D., Liu, B., Tan, M., Li, J., Wang, S. S., and Hung, M. C. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to taxol via mdr-1-independent mechanisms. Oncogene, 13: 1359-1365, 1996.
33. Pegram, M. D., Finn, R. S., Arzoo, K., Beryt, M., Pietras, R. J., and Slamon, D. J. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer ceils. Oncogene, 15: 537-547, 1997.
34. Archer, C. D., Ellis, P. A., Dowsett, M., and Smith, I. E. c-erbB-2 positivity correlates with poor apoptotic response to chemotherapy in primary breast cancer. Breast Cancer Res. Treat., 50: 237, 1998.
35. Krainer, M., Brodowicz, T., Zeillinger, R., Wiltschke, C., Scholten, C., Seifert, M., Ernst Kubista, E., Christoph, C., and Zielinski, C. C. Tissue expression and serum levels of HER-2/neu in patients with breast cancer. Oncology, 54: 475-481, 1997.
36. Lonn, U., Lonn, S., Ingelmann-Sundberg, H., Nilsson, B., and Stenkvist, B. c-erbB-2/int-2 amplification appears faster in breast-cancer patients receiving second-line endocrine treatment. Int. J. Cancer, 69: 273-277, 1996.
37. Hayes, D. F., and Trock, B. Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res. Treat., 52: 305-319, 1998.
38. Baselga, J., Norton, L., Albanell, J., Kim, Y. M., and Mendelsohn, J. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res., 58: 2825-2831, 1998.
39. Arteaga, C. L., Winnier, A. R., Poirier, M. C., Lopez-Larraza, D. M., Shawver, L. K., Hurd, S. D., and Stewart, S. J. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. Cancer Res., 54: 3758-3765, 1994.
40. Slamon, D., Leyland-Jones, B., Shak, S., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Baselga, J., and Norton, L. Addition of herceptin (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/mbc) markedly increases anticancer activity: a randomized, multinational controlled Phase III trial. Proc. Am. Soc. Clin. Oncol., 77: 98, 1998.